Facebook Twitter YouTube Google Plus

Research Projects Funded by the Meso Foundation

The Mesothelioma Applied Research Foundation has been instrumental in providing seed money for mesothelioma research when almost no other research funds for this cancer were available. The Meso Foundation's funding objectives are twofold: to directly fund basic mesothelioma research and support mesothelioma clinical trials in worthy, peer-reviewed, projects as well as to stimulate additional federal research funding opportunities.

To date the Meso Foundation has funded over $10 million in research projects across the globe. It takes a number of years to move from the bench to the bedside but as the Meso Foundation's research grant program matures it is helping to open up exciting new clinical trials available to patients now.

Use this search box to find research funded by the Mesothelioma Applied Research Foundation. 

Online Database by Caspio
Click here to load this Caspio Online Database.

Below, we have also listed all grant recipients sorted by last name. 

Prasad Adusumilli, MD, Memorial Sloan Kettering Cancer Center
WT-1 targeted adoptive T-cell therapy for malignant pleural mesothelioma, 2009 Lance S. Ruble Memorial Grant
CAR T cells with TGF-ß resistant cell-intrinsic strategies for mesothelioma, 2016, Craig Kozicki Memorial Grant

H. Richard Alexander, MD, University of Maryland
Inhibition of Il-1 as a Novel Target in Peritoneal Mesothelioma, 2008

Deborah Altomare, PhD, Fox Chase Cancer Center
Combinatorial Targeting of Signaling Pathways that are Frequently Implicated in Malignant Mesothelioma, 2006

Samuel G. Armato III, PhD
Computerized Analysis of Mesothelioma on Thoracic Computed Tomography Scans, 2001

Paul Baas, MD, PhD, Netherlands Cancer Institute, The Netherlands
Malignant Mesothelioma and Thalidomide; A Translational Research Project, 2004

Dario Barbone, PhD, The Regents of the University of California, San Francisco
Role of ANXA4, ASS1 & MVP Genes in Mesothelioma 3D Multicellular Resistance, 2012 Belluck & Fox Grant

Muralidhar Beeram, MD and Johann Sebastian de Bono, MD, PhD, University of Texas at San Antonio
Pharmacogenetic and Pharmacogenomic Studies of Thymidylate Synthase Enhancer Region Polymorphisms in Mesothelioma and Their Therapeutic Implications in Patients Treated with Pemetrexed Sodium, 2002

Brad Black, MD, Center for Asbestos Related Diseases
SMRP Serum Levels in Asbestos-Exposed Libby Montana Area Residents, 2004

Alain Borczuk, MD, Columbia University Medical Center
Poor Prognosis Gene Expression Signatures Suggest Molecular Pathways of Mesothelioma Progression and Potential Therapeutic Targets, 2007

Courtney Broaddus, MD, University of California, San Francisco
The use of novel mesothelioma-specific antibodies for diagnostic and therapeutic preclinical studies, 2006

Raphael Bueno, MD, Harvard Medical School and Brigham and Womens Hospital
Validation of Prognostic Markers in Mesothelioma, 2001

Cecilia Camacho-Hubner, MD, St. Bartholomews Hospital, William Harvey Research Institute, University of London, England
Development of Novel Therapeutic Strategies for Malignant Pleural Mesothelioma: Targeting the IGF System, 2004

Robert Cameron, MD, UCLA Medical School
Comparison Of Adjuvant Treatments For Mesothelioma, Including Hyperthermia, COX-2 Inhibition, Cpil-4 Toxin Therapy, And Standard Chemotherapy, 2004
National Mesothelioma Data/Tissue Bank Pilot Project, 2001

Xiaobo (Paul) Cao, MD, Scott White Memorial Hospital - Texas A&M University
Inhibiting bcl-xl in Mesothelioma by Small-Molecule BCL-2/BCL-XL Antagonists, 2005

Mitchell Cheung, PhD, The Research Institute of Fox Chase Cancer Center
BAP1 Mesothelioma Mouse Models and Personalized Therapeutics, 2012 The Anderson Family Grant

Yolanda Colson, MD, PhD, Brigham and Women’s Hospital
Tumor-Localizing Polymeric Nanoparticle Drug Delivery for the Treatment of Malignant Mesothelioma, 2010

Cancer Research and Biostatistics (CRAB)/IASLC
Proposal for a Pilot Study on the Use of Tumor Volume Measurement from CT Scans for the Clinical Staging of Malignant Pleural Mesothelioma (MPM), 2012 Judith L. Lagana Memorial Grant
International Mesothelioma Staging Project, phase 2, 2009
International Mesothelioma Staging Project, phase 1, 2008

David T. Curiel, MD, PhD, University of Alabama at Birmingham
Targeted Virotherapy for Mesothelioma, 2003

Tao Dao, MD, PhD, Memorial Sloan Kettering Cancer Center
TCR-like mAb specific for WT1 peptide/MHC complexes on mesothelioma, 2011
Specific immunotherapy for mesothelioma by use of a bi-specific TCR-like antibody, 2013

Marc de Perrot, MD, University of Toronto
Development of a Novel Therapeutic Strategy with Pemetrexed and Regulatory T cell Depletion for Malignant Pleural Mesothelioma: A Translational Research Project, 2007
Optimizing the radiation approach to mesothelioma with immunotherapy, 2013

Assunta DeRienzo, Brigham and Women's Hospital
Identification of Novel Mutations in Malignant Pleural Mesothelioma using Deep Whole-Genome Sequencing, 2011

Faris Farassati, PhD, PharmD, University of Minnesota Medical School
Silencing Mesothelin: A Novel Approach for Treatment of Mesothelioma, 2006

Adi Gazdar, MBBS, University of Texas Southwestern Medical Center
Establishment of Immortalized Mesothelial Cell Lines: A Unique Resource for the Study of Mesothelioma, 2007

Giovanni Gaudino, PhD, University of Piedmonte Novara Italy
Novel Pharmacological Targets for Malignant Mesothelioma, 2005

Filippo Giancotti, MD, PhD, Memorial Sloan-Kettering Cancer Center
Preclinical Efficacy of a TOR/PI-3K inhibitor in Malignant Mesothelioma, 2012 The Law Offices of Peter G. Angelos Grant

Antonio Giordano PhD, University of Trieste, Italy
PRMT5 as two-in-one strategy for mesothelioma treatment, 2016 

Elisa Giovannetti, MD, PhD, VU University Medical Center
Novel lactate dehydrogenase inhibitors for the treatment of mesothelioma, 2013 The Law Offices of Peter G. Angelos Grant

David I. Goldman, MD, Albert Einstein Collge of Medicine of Yeshiva University
The Role of the Proton-Coupled Folate Transporter (PCFT) as a Determinant of the Activity of Pemetrexed in Mesothelioma, 2007
Pemetrexed: Cellular Pharmacology and Mechanisms of Resistance in Mesothelioma; Role of Methylathioadenosine Phosphorylase, 2004 Alvin Rehbeck Memorial Grant

Gavin J. Gordon, PhD, Harvard Medical School/Brigham and Women's Hospital
Gene Therapy in Mesothelioma, 2003

Michael Harbut, MD, MPH, FCCP, National Center for Vermiculite and Asbestos-Related Cancers, Karmanos Cancer Institute, 2012

Joost Hegmans, PhD, Erasmus Medical Center, The Netherlands
Macrophage recruitment/polarization as a prognostic and therapeutic target, 2012 Larry Davis Memorial Grant

Nicholas H. Heintz, PhD, The University of Vermont and State Agricultural College
Molecular Targets of Thiostrepton in Malignant Mesothelioma, 2009 John Sterling Memorial Grant

Mitchell Ho, PhD, National Cancer Institute, NIH
Targeting Mesothelin by Human Antibodies for Mesothelioma Treatment, 2007 Craig Kozicki Memorial Grant

Chuong Hoang, MD, Stanford University
Mesothelioma Biomarker Development Drive by microRNA-mRNA Regulatory Module Network Analysis, 2010

Tan A. Ince, MD, PhD, Whitehead Institute Massachusetts Institute of Technology
Genetically engineered human mesothelioma cells, 2005

Sergey Ivanov, PhD, NYU School of Medicine
ROMA for the Identification of Genes Associated with Early Stages and Progression of Asbestos-Induced Pleural Malignant Mesothelioma, 2007

Alla Ivanova, MD, New York University
Mechanisms of innate drug sensitivity in malignant pleural mesotheliomas, 2006

Ramasamy Jagadeeswaran, MD, University of Chicago
Paxillin is a Potential Molecular Therapeutic Target in Malignant Pleural Mesothelioma (MPM), 2007

Pasi Janne, MD, PhD, Dana-Farber Cancer Institute
Identifying critical activators of PI3K/Akt signaling pathway in mesothelioma, 2005

Il-Jin Kim, PhD, The Regents of the University of California, San Francisco
Fusion genes as therapeutic targets in malignant pleural mesothelioma, 2012 The Bankhead Family Fund of the Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Oberman, Satterley & Bosl Foundation Grant

Hedy Lee Kindler, MD, University of Chicago
A Study of Biologic Markers of Angiogenesis during a Phase II Trial of the VEGF Receptor Inhibitor SU5416 in Malignant Mesothelioma, 2000

Richard Kornbluth, MD, Veterans Medical Research Foundaton
Immunotherapy With Soluble, Multimeric CD40L and Other TNFSF Ligands, 2004

Robert Kratzke, MD, University of Minnesota
Targeting Cap-Mediated Translation for Mesothelioma Therapy, 2007 Christopher Stoeckler Memorial Grant

Lee M. Krug, MD, Memorial Sloan-Kettering Cancer Center
Randomized phase II study of adjuvant WT-1 analog peptide vaccine in patients with malignant pleural mesothelioma after completion of combined modality therapy, 2009
WT-1 Analog Peptide Vaccine in Patients with Malignant Mesothelioma, 2006

Marc Ladanyi, Memorial Sloan-Kettering Cancer Center
Frequent inactivation of BAP1 in mesothelioma: biology and new therapeutic opportunities, 2011 Ron Simkins Memorial Grant

Ite Laird-Offringa, PhD, University of Southern California, USC/Norris Cancer Center
Rapid Screening of DNA Methylation Markers for Accurate Molecular Diagnosis of Mesothelioma, 2005
Molecular Diagnosis of Mesothelioma Using DNA Methylation Signatures, 2002

B. Lambrecht, MD, Erasmus Medical Center, The Netherlands
Dendritic Cell-Based Immunotherapy of Human Mesothelioma, 2005
Dendritic Cell-Based Immunotherapy of Mesothelioma, 2003

Stephen Levin, MD, Mount Sinai School of Medicine
Serum Specimen Identification and Mortality Experience Update among Asbestos Insulators for Validation of Mesothelioma Biomarkers, 2006

Fengzhi Li, PhD, Roswell Park Cancer Institute
Validation of a novel antiapoptotic protein inhibitor for mesothelioma treatment, 2010

Bin Liu, PhD, University of California at San Francisco
Internalizing scFv-targeted intracellular delivery of small RNA therapeutics to all subtypes of mesothelioma, 2010 Lance S. Ruble & Ferraro Law Firm Grant
Establishing the molecular identity of a panel of internalizing mesothelioma cell surface antigens, 2006
Defining and Targeting Mesothelioma-Specific Internalizing Cell Surface Receptors for Novel Therapeutics, 2004

Gang Logan Liu, PhD, University of Illinois at Urbana-Champaign
Enhanced Diagnostic Imaging and High Precision Gene Therapy of Mesothelioma Using Nontoxic Nanocarriers, 2008

Bo Lu, MD, PhD, Vanderbilt University Medical Center
Radiation Sensitization Via Inhibiting Survival of Mesothelioma and its Vascular Endothelium, 2003

Miguel Manzanares, PhD, New York University School of Medicine
Blocking post-translational modifications of p27 for mesothelioma therapy, 2017

Carmen J. Marsit, PhD, Brown University, Division of Biology and Medicine
Array-Based miRNA Expression and Methylation Profiling of Normal and Tumorigenic Pleural Mesothelium, 2007

Larry H. Matherly, PhD, Wayne State University
Targeting malignant pleural mesothelioma with PCFT-targeted therapeutics, 2009

Ronit Mazor, PhD, National Cancer Institute, Center for Cancer Research Bethesda, MD, United States
Improving immunotoxin therapy of mesothelioma, 2016 

J. Andrea McCart, MD, University Health Network - Toronto General Research Institute
Development of a novel virotherapy strategy to detect and treat malignant peritoneal mesothelioma, 2009 Ken Bendix Memorial Grant

Laura Moro, PhD, University of Piemonte Orientale "A.Avogadro", Italy
Tumor Repressive Functions of Estrogen Receptor Beta in Malignant Pleural Mesothelioma, 2009

Brooke Mossman, PhD, University of Vermont & State Agricultural College
Nanoporous Spheres for Chemotherapeutic Drug Delivery in Mesothelioma Patients, 2006

Steven Mutsaers, MD, PhD, Lung Institute of Western Australia
The Hedgehog Signaling Pathway As A Target For Inhibiting Malignant Mesothelioma Growth, 2008

Delia Nelson, PhD, Curtin University
Angio-immuno Agents and Their Effects in Malignant Mesothelioma, 2005

Jill Ohar, MD, Wake Forest University School of Medicine
Consortium for the sharing of germ line DNA and tissue from subjects with mesothelioma, 2010 Franz Losch Memorial Grant
Phenotypic and Genotypic Determinants to Identify Patients at High Risk for Mesothelioma, 2003

Christian Ottensmeier, University of Southampton, United Kingdom
Evaluating the effect of immunity on outcomes of patients with mesothelioma, 2013 The Lance S. Ruble, Jannelle Bedel and Ferraro Law Firm Grant

Gregory Otterson, MD, Ohio State University Research Foundation
Epigenetic Changes in Mesothelioma, 2004

Harvey Pass, MD, Karmanos Cancer Institute
Soluble Mesothelin/MPF Related Protien (SMR) Levels in Mesothelioma: A MARF Collaborative Study for Definition of Biomarker Classification and Use in Therapy Monitoring, 2004

Manish R. Patel, DO, University of Minnesota
Evaluation of predictive biomarkers and the host immune response to intrapleural administration of oncolytic Measles virus in a phase I clinical trial specifically for patients with mesothelioma, 2010 Beth Ann Miller Memorial Grant

Ellinor Peerschke, PhD, Memorial Sloan Kettering Cancer Center
gC1qR/HABP1/p32: A novel therapeutic target for mesothelioma, 2017

Usha Pendurthi, PhD, The University of Texas Health Science Center at Tyler
Endothelial Cell Protein C Receptor Attenuates Mesothelioma Progression, 2013

Katherine F. Roby, PhD, University of Kansas Medical Center
HSP90 Targeted Therapy for Mesothelioma, 2009

Ravi Salgia, MD, PhD, University of Chicago
EPHA2 as A Novel Therapeutic Target in Malignant Pleural Mesothelioma, 2014
Protein Kinase C as a Novel Therapeutic Target in Mesothelioma, 2007 Jeffrey P. Hayes Memorial Grant
Studies of c-Met in Mesothelioma, 2004

Bernadette Scott, PhD, Monash University Clayton Victoria, Australia
Pre-Clinical Studies of a Novel Therapeutic Strategy for Malignant Mesothelioma, 2004

Tanguy Seiwert, MD, University of Chicago
The T-cell inflamed immune microenvironment in Malignant Mesothelioma, 2014

Sunil Sharma, MD, Nevada Cancer Institute
Histone Deacetylase (HDAC) in Malignant Mesothelioma, 2005

Arti Shukla, PhD, University of Vermont and State Agricultural College
Bifunctionalized APMS Particles to Target ERK5 in Malignant Mesothelioma Treatment, 2009

Daniel Sterman, MD, New York University School of Medicine New York, NY
Lymph Node Immunophenotyping In Malignant Pleural Mesothelioma, 2016, The Lance S. Ruble, Donald E. Smitley, Craig S. Kozicki & Ferraro Law Firm Research Grant 

Joseph Testa, PhD, Fox Chase Cancer Center
Combinatorial Targeting of Tyrosine Kinases that are Aberrantly Activated in Malignant Mesothelioma, 2008
Identification of a 1p22 Tumor Suppressor Locus Frequently Deleted in Malignant Mesothelioma, 2000

Anil Vachani, MD, University of Pennsylvania
Discovery and Validation of Novel Serological Biomarkers in Mesothelioma, 2005

Sheelu Varghese, PhD, University of Maryland School of Medicine
Pre-Clinical Development of a Novel Therapy for Malignant Peritoneal Mesothelioma, 2010

Anil Wali, PhD, Wayne State University/Karmanos Cancer Institute
The Ubiquitin-Proteasome Pathway in Mesothelioma, 2006

Liang-Chuan S Wang, Perelman School of Medicine at the University of Pennsylvania
The Role of the IFN response in Chemosensitivity of Mesothelioma to Pemetrexed, 2011

Guang-Hui Xiao, MD, PhD, Fox Chase Cancer Center
Adenovirus-mediated NK4 gene therapy for malignant mesothelioma, 2006

Haining Yang, PhD, University of Hawaii
Studies of Tumor Necrosis Factor alpha as a New Target for Human Malignant Mesothelioma Prevention and Therapeutic Strategies, 2008

Travis Young, PhD, California Institute for Biomedical Research
Controllable CAR-T Therapy for Mesothelioma, 2014 Ken Bendix Memorial Grant

Nadia Zaffaroni, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Identification and validation of miRNAs as novel biomarkers and therapeutic targets in diffuse malignant peritoneal mesothelioma, 2011